89bio, Inc. Board of Directors

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Mr. Francis W. Sarena

Mr. Francis W. Sarena

Chief Operating Officer

Ms. Annie J. Chang M.B.A.

Ms. Annie J. Chang M.B.A.

VP of Investor Relations & Corporate Communications

Ms. Amanda Kurihara

Ms. Amanda Kurihara

Vice President of People & Culture

Ms. Melissa Abel

Ms. Melissa Abel

Senior Vice President of Commercial Strategy

Mr. Quoc Le-Nguyen

Mr. Quoc Le-Nguyen

Chief Technical Officer

Mr. Shiva K. Natarajan CPA

Mr. Shiva K. Natarajan CPA

Senior Vice President of Finance & Principal Accounting Officer

Mr. Paul Shin

Mr. Paul Shin

Senior Vice President of R&D Operations

Dr. Harry Mansbach M.D.

Dr. Harry Mansbach M.D.

Chief Medical Officer

Mr. Ryan Stephen Martins

Mr. Ryan Stephen Martins

Chief Financial Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.